Recap: Acasti Pharma Q4 Earnings
Portfolio Pulse from Benzinga Insights
Acasti Pharma (NASDAQ:ACST) reported Q4 earnings with in-line EPS of $-0.11 and revenue down $0 from the same period last year. Last quarter, the company beat EPS estimates by $0.02, followed by a 3.69% drop in share price the next day.
June 23, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Acasti Pharma reported Q4 earnings with in-line EPS of $-0.11 and no change in revenue YoY. Last quarter's EPS beat resulted in a 3.69% share price drop.
Acasti Pharma's Q4 earnings report showed in-line EPS and no change in revenue compared to the same period last year. Given that the stock price dropped 3.69% after last quarter's EPS beat, it is uncertain how the market will react to this in-line report. Therefore, the short-term impact on the stock price is neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100